SciSparc Ltd Ordinary Shares SPRC 深 滬
等待開盤 10-31 09:30:00 美东时间
3.25
-0.150
-4.41%
華盛通- 最 高3.43
- 今 開3.39
- 成交量 4.21万股
- 最 低 3.23
- 昨 收 3.40
- 總市值 3648.39万
- 52周最高 37.59
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 1.75
- 委 比 -71.12%
- 總股本 1122.58万
- 歷史最高 3865.68
- 量 比 0.41
- 振 幅 5.88%
- 歷史最低 3.23
- 每 手 1
- 風險率 2.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
N2OFF Inc. announces the completion of its merger with MitoCareX Bio Ltd, a biotech company focused on developing novel cancer therapies targeting mitochondrial SLC25 proteins. The transaction, valued at $700,000, makes MitoCareX a wholly-owned subsidiary of N2OFF, with the sellers receiving 40% of N2OFF’s fully diluted capital stock. N2OFF plans to support MitoCareX’s operations for the first two years. MitoCareX’s proprietary MITOLINE™ algorith...
10-30 13:25
N2OFF Closes Merger With MitoCareX Bio, Expanding Into Cancer Drug Discovery Targeting The Mitochondrial SLC25 Protein Family
N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger with MitoCareX Bio
10-23 20:26
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
SciSparc Ltd. announce the sale of its subsidiary MitoCareX Bio Ltd. to N2OFF, Inc. MitoCareX focuses on developing novel cancer therapies targeting mitochondrial SLC25 proteins, utilizing its proprietary MITOLINE™ algorithm. The sale includes transferring 6,622 shares for $700,000 and exchanging remaining shares for 40% of N2OFF's common stock. SciSparc and other sellers will receive milestone-based payments up to 25% of N2OFF's common stock and...
10-23 20:03
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
SciSparc Ltd. and Clearmind Medicine Inc. have collaboratively published a U.S. patent application for a combination therapy using MEAI and PEA to address binge behavior disorders, including excessive alcohol consumption, eating disorders, and substance addictions. The therapy harnesses MEAI's psychedelic properties and PEA's anti-inflammatory effects, aiming to offer a breakthrough treatment without traditional intervention risks. SciSparc focus...
10-20 11:41
SciSparc to Acquire Controlling Stake in Miza III Ventures, SciSparc Transfers Advanced Drug Portfolio to Miza in $11.6M Deal
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system,
10-15 19:07
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
SciSparc Ltd. has entered into a definitive asset and share purchase agreement with Miza III Ventures Inc., under which SciSparc will transfer its advanced clinical stage pharmaceutical portfolio and a 51% stake in SciSparc Nutraceuticals Inc. to Miza in exchange for a controlling interest (75%-84%). The transaction also includes SciSparc committing up to CAD1,000,000 in capital via a convertible note. Upon closing, Miza will rename to "NeuroTher...
10-15 11:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 46.4% to $0.37 during Tuesday...
10-15 05:06
SciSparc And AutoMax Call Off Merger
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.
10-06 20:55
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
SciSparc Ltd. has entered into a framework agreement with AutoMax Motors Ltd. to terminate their merger agreement and establish repayment terms for outstanding loans. Under the agreement, AutoMax will repay a $4.25 million loan by January 1, 2028, including 9% annual interest, and a $2.0 million loan through monthly installments starting November 20, 2025, with 8% annual interest. SciSparc focuses on developing cannabinoid-based therapies for cen...
10-06 10:40
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
SciSparc Ltd. announced that N2OFF, Inc. stockholders approved the acquisition of SciSparc's majority owned subsidiary, MitoCareX Bio Ltd. MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 family. The acquisition, valued at $700,000 and 40% of N2OFF’s fully diluted capital stock, is expected to close in October 2025, pending final conditions. N2OFF will also provide $1 milli...
09-29 20:03
